Javier Cortés, MD, PhD, discusses the final KEYNOTE-522 analysis, showing pembrolizumab plus chemotherapy sustains long-term survival benefit in early-stage TNBC.
Javier Cortés, MD, PhD
Advertisement
Javier Cortés is the Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials.
Articles by Javier Cortés, MD, PhD
How KEYNOTE-522 Permanently Changed Triple-Negative Breast Cancer Care
Published: | Updated:
Discover the final 7.8-year survival data from KEYNOTE-522 and see how adding pembrolizumab to chemotherapy drastically cuts recurrence for early TNBC.
Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Advertisement
Latest Updated Articles
How KEYNOTE-522 Permanently Changed Triple-Negative Breast Cancer CarePublished: May 30th 2026 | Updated: August 24th 2026
- How KEYNOTE-522 Permanently Changed Triple-Negative Breast Cancer Care
Published: May 30th 2026 | Updated: August 24th 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
3
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
4
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
5